Epidermolysis Bullosa Acquisita (Acquired Epidermolysis Bullosa)

Subscribe to Selected New Research on Epidermolysis Bullosa Acquisita

281 relevant articles (7 outcomes, 18 trials/studies) found for this Disease

Description: Form of epidermolysis bullosa characterized by trauma-induced, subepidermal blistering with no family history of the disease. Direct immunofluorescence shows IMMUNOGLOBULIN G deposited at the dermo-epidermal junction.

Also Known As:

Acquired Epidermolysis Bullosa; Epidermolysis Bullosa, Acquired

Relationship Network

Disease Context: Research Results

Congenital, Hereditary, and Neonatal Diseases and Abnormalities: 449

Congenital Abnormalities: 10008

Skin Abnormalities: 78

Epidermolysis Bullosa: 383

Epidermolysis Bullosa Acquisita: 281

Skin and Connective Tissue Diseases

Skin Diseases: 6187

Vesiculobullous Skin Diseases: 223

Epidermolysis Bullosa: 383

Epidermolysis Bullosa Acquisita: 281

Skin Abnormalities: 78

Epidermolysis Bullosa: 383

Epidermolysis Bullosa Acquisita: 281

Genetic Skin Diseases: 11

Epidermolysis Bullosa: 383

Epidermolysis Bullosa Acquisita: 281

Related Diseases

1.	Lichen Planus (Lichen Ruber Planus)
2.	Atopic Dermatitis (Atopic Eczema)
3.	Pyoderma Gangrenosum
4.	Psoriasis (Pustulosis Palmaris et Plantaris)
5.	Glycogen Storage Disease Type VI (Glycogenosis Type VI)

Experts

1.	Chen, Mei: 6 articles (01/2008 - 05/2002)
2.	Woodley, David T: 6 articles (01/2008 - 05/2002)
3.	Remington, Jennifer: 4 articles (01/2008 - 06/2006)
4.	Hashimoto, T: 4 articles (11/2006 - 11/2001)
5.	Zillikens, Detlef: 3 articles (08/2008 - 12/2004)
6.	Hashimoto, Takashi: 3 articles (01/2006 - 03/2004)
7.	Sitaru, Cassian: 2 articles (08/2008 - 12/2004)
8.	Hou, Yingping: 2 articles (06/2007 - 06/2006)
9.	Bandyopadhyay, Pubali: 2 articles (06/2007 - 06/2006)
10.	Doostan, Arvin: 2 articles (06/2007 - 06/2006)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Epidermolysis Bullosa Acquisita:

1.	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/01/1990 - "Intractable epidermolysis bullosa acquisita: efficacy of cyclosporin A." 03/01/2001 - "Epidermolysis bullosa acquisita responsive to cyclosporin therapy." 06/01/1991 - "Clearing of epidermolysis bullosa acquisita with cyclosporine." 03/01/1990 - "Clearing of epidermolysis bullosa acquisita with cyclosporine." 11/01/1988 - "Although its mechanism of action in epidermolysis bullosa acquisita is unknown, we propose that cyclosporine may be a helpful drug for patients whose disease is refractory to more traditional forms of therapy." Order ALL the reference details at left...
2.	Intravenous Immunoglobulins (IVIG)FDA Link 11/01/1994 - "Epidermolysis bullosa acquisita: efficacy of high-dose intravenous immunoglobulins." 08/01/1993 - "Epidermolysis bullosa acquisita: efficacy of high-dose intravenous immunoglobulins." 01/01/2002 - "Epidermolysis bullosa acquisita: treatment with intravenous immunoglobulins." 05/01/1995 - "Successful treatment of epidermolysis bullosa acquisita using intravenous immunoglobulins." 12/01/1998 - "Severe, refractory epidermolysis bullosa acquisita complicated by an oesophageal stricture responding to intravenous immune globulin." Order ALL the reference details at left...
3.	Collagen Type VIIIBA 06/01/2002 - "This study sought to determine if type VII collagen, the epidermolysis bullosa acquisita autoantigen, was present in normal human colon by western blotting and immunofluorescence. " 01/01/2008 - "Epidermolysis bullosa acquisita (EBA) is an acquired, mechanobullous disease characterized by autoimmunity to type VII collagen. " 01/01/2008 - "Autoimmunity to type VII collagen: epidermolysis bullosa acquisita." 10/01/2007 - "Autoimmunity to type VII collagen: epidermolysis bullosa acquisita." 01/01/2003 - "Epidermolysis bullosa acquisita results from autoimmunity to type VII collagen in the anchoring fibrils of the basement membrane area. " Order ALL the reference details at left...
4.	AntibodiesIBA 05/01/1990 - "In this study a variety of immunoelectron microscopic methods were used to define the precise ultrastructural binding site of epidermolysis bullosa acquisita antibodies (EBA-Ab). " 01/01/1998 - "Epidermal-binding circulating antibodies in epidermolysis bullosa acquisita: what are they?" 04/01/1997 - "Epidermolysis bullosa acquisita associated with epidermal-binding circulating antibodies." 01/01/1994 - "For epidermolysis bullosa acquisita and dermal-binding antibodies skin can be split at room temperature." 12/01/1991 - "Circulating anti-glomerular basement membrane antibodies in coeliac disease and epidermolysis bullosa acquisita." Order ALL the reference details at left...
5.	Colchicine FDA LinkGeneric 02/01/2005 - "Remission of recalcitrant epidermolysis bullosa acquisita (EBA) with colchicine monotherapy." 05/01/1996 - "Colchicine for epidermolysis bullosa acquisita." 01/01/1994 - "Epidermolysis bullosa acquisita--successful treatment with colchicine." 01/01/1989 - "[Value of colchicine in treating acquired epidermolysis bullosa]" 02/01/2005 - "A 42-year-old woman with widespread recalcitrant epidermolysis bullosa acquisita (EBA) responded well to colchicine monotherapy after attempts to control her disease with other modalities failed. " Order ALL the reference details at left...
6.	Monoclonal AntibodiesIBA 02/01/2007 - "Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies)." 09/01/1991 - "Immunofluorescence mapping was performed using polyclonal antibodies from the serum of patients with bullous pemphigold and epidermolysis bullosa acquisita and monoclonal antibodies against GB3 antigen and collagen type VII. All but the bullous pemphigold serum gave positive results; only faint and focal staining of the dermoepidermal junction was observed with bullous pemphigold serum. " Order ALL the reference details at left...
7.	Gb3 antigenIBA 09/01/1991 - "Immunofluorescence mapping was performed using polyclonal antibodies from the serum of patients with bullous pemphigold and epidermolysis bullosa acquisita and monoclonal antibodies against GB3 antigen and collagen type VII. All but the bullous pemphigold serum gave positive results; only faint and focal staining of the dermoepidermal junction was observed with bullous pemphigold serum. " Order ALL the reference details at left...
8.	AntigensIBA 07/01/2004 - "BACKGROUND: Epidermolysis bullosa acquisita (EBA) can be differentiated from other subepidermal bullous diseases by sophisticated techniques such as immunoelectron microscopy, salt-split skin antigen mapping, fluorescence overlay antigen mapping, immunoblot and enzyme-linked immunosorbent assay. " 03/01/1998 - "The diagnosis of epidermolysis bullosa acquisita was confirmed by split mapping, fluorescence overlay antigen mapping and Western blot." 09/01/1986 - "Epidermolysis bullosa acquisita is an autoimmune blistering disease with the distinct feature of having an autoantibody directed against an antigen located below the basement membrane of human skin and mucous membrane. " 02/01/1996 - "BACKGROUND AND DESIGN: From previous studies, we concluded that the fluorescence overlay antigen mapping (FOAM) technique could be of value to the differential diagnosis of the acquired subepidermal bullous skin disorders, bullous pemphigoid (BP) and epidermolysis bullosa acquisita (EBA). " 06/01/2007 - "Epidermolysis bullosa acquisita (EBA) is an organ-specific autoimmune disease with a well-defined antigen-autoantibody system. " Order ALL the reference details at left...
9.	AutoantibodiesIBA 06/01/2006 - "Induction of epidermolysis bullosa acquisita in mice by passive transfer of autoantibodies from patients." 06/15/2001 - "Furthermore, autoantibodies from epidermolysis bullosa acquisita patients also reacted with NC2/COL. " 05/01/1995 - "Passive transfer of autoantibodies from a patient with mutilating epidermolysis bullosa acquisita induces specific alterations in the skin of neonatal mice." 04/01/1993 - "We also found that separation of the DEJ with brief exposure of skin to 56 degrees C provided a useful substrate for testing the autoantibodies in the sera of patients with epidermolysis bullosa acquisita (EBA). " 06/01/1987 - "Autoantibodies in the skin and sera of patients with epidermolysis bullosa acquisita bind to a large matrix molecule within the lamina densa region of skin basement membrane. " Order ALL the reference details at left...
10.	Immunoglobulin A (IgA)IBA 01/01/2009 - "Mixed immunobullous disorder most consistent with the IgA-form of epidermolysis bullosa acquisita." 12/01/2002 - "A diagnosis of IgA-mediated epidermolysis bullosa acquisita (IgA-EBA) was made. " 12/01/2002 - "IgA-mediated epidermolysis bullosa acquisita: two cases and review of the literature." 11/01/1999 - "Ocular involvement in IgA-epidermolysis bullosa acquisita." 07/01/1997 - "Immunoelectron microscopy revealed IgA deposits in the sublamina densa area similar to those seen in epidermolysis bullosa acquisita. " Order ALL the reference details at left...

Therapies and Procedures

1.	Photopheresis 09/01/1995 - "Remission of severe epidermolysis bullosa acquisita induced by extracorporeal photochemotherapy." 03/01/1997 - "Treatment of refractory epidermolysis bullosa acquisita with extracorporeal photochemotherapy." Order ALL the reference details at left...
2.	Lasers (Laser) 05/01/2007 - "Two patients with localized epidermolysis bullosa acquisita: diagnostic value of laser scanning confocal microscopy." 04/01/1998 - "Application of confocal laser scanning microscopy to differential diagnosis of bullous pemphigoid and epidermolysis bullosa acquisita." 08/01/2003 - "CONCLUSIONS: Laser scanning confocal microscopy allows precise localization of in vivo-bound IgG in patients' skin and, thus, it is a rapid method for the differentiation of mucous membrane pemphigoid from bullous pemphigoid and epidermolysis bullosa acquisita. " 04/01/1998 - "We applied confocal laser scanning microscopy to fluorescence overlay antigen mapping (FOAM) for differential diagnosis of bullous pemphigoid (BP) and epidermolysis bullosa acquisita (EBA). " Order ALL the reference details at left...
3.	Tracheostomy 11/01/1993 - "The case is reported of a 56-year-old man with epidermolysis bullosa acquisita (EBA) who developed such severe involvement of the upper respiratory tract that a tracheostomy had to be performed. " 09/01/2001 - "Laryngeal epidermolysis bullosa acquisita requiring tracheostomy presenting with an acquired factor VIII coagulopathy." 11/01/1993 - "Epidermolysis bullosa acquisita--a case with upper airways obstruction requiring tracheostomy and responding to cyclosporin." Order ALL the reference details at left...
4.	Plasma Exchange 05/01/1986 - "Thus plasma exchange therapy may be a useful adjunct to conventional treatments for patients with epidermolysis bullosa acquisita." 05/01/1986 - "Epidermolysis bullosa acquisita: clinical response to plasma exchange therapy and circulating anti-basement membrane zone antibody titer." 02/01/1997 - "We describe a case of severe epidermolysis bullosa acquisita of 7 years' duration that had been treated with azathioprine, corticosteroids, chlorambucil, plasma exchanges, cyclophosphamide, cyclosporine, and colchicine without any lasting effect. " Order ALL the reference details at left...
5.	Transplants (Transplant) 02/01/1988 - "These findings suggest a disease process confined to skin graft recipient sites with features identical to those previously described with recessive dystrophic or immunofluorescence-negative acquired epidermolysis bullosa." Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Epidermolysis Bullosa Acquisita

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 7 Outcomes
Top 200 Key Drugs and Biologics
Top 7 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>